The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly.Top 5 Upgrades: BTIG upgraded CoStar Group (CSGP) to Buy from Neutral with an $80 price target. Expectations are low, investment is past peak, Homes.com is gaining momentum and the firm thinks an upcoming AI-driven product update could resonate, the firm tells investors.Needham upgraded Teleflex (TFX) to Buy from Hold with a $138 ...

NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Teleflex Incorporated (“Teleflex” or the “Company”) (NYSE: TFX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Teleflex and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On January ...

Core Insights - Teleflex has parted ways with CEO Liam Kelly, appointing Stuart Randle as interim president and CEO while searching for a permanent replacement [3][8] - The leadership change is part of a transformation strategy following the announcement of divesting three business units for approximately $2 billion [5][8] - Teleflex has revised its revenue guidance for 2025 to $3.27 billion to $3.28 billion, down from a previous estimate of $3.31 billion to $3.32 billion, citing softer demand for certain medical devices [7][8] Leadership Changes - Liam Kelly, who became CEO in 2018, has left the company without a permanent successor [3] - Stuart Randle, a board member since 2009 and former CEO of Ivenix, has been appointed as interim president and CEO [4][5] - Stephen Klasko has taken over as chairman of the board following Kelly's departure [3] Business Strategy - Teleflex is in the process of closing the $1.5 billion sale of its OEM business and the $530 million sale of its acute care and interventional urology units [5][6] - The divestitures will allow Teleflex to focus on its vascular access, interventional, and surgical businesses [6] Financial Outlook - The company expects a revenue reduction of just over 1% at the midpoint due to lower-than-expected demand for intra-aortic balloon pumps and catheters in the U.S. and Asia [7] - The revised revenue guidance reflects challenges in the OEM business and delays in purchase orders [7]

Core Viewpoint - Teleflex Incorporated (TFX) experienced a significant decline in share price following leadership changes and a lowered revenue outlook for the year [1]. Group 1: Leadership Changes - Stuart Randle has been appointed as Interim President and Chief Executive Officer, effective immediately, succeeding Liam Kelly, who has stepped down from his roles as Chairman, President, and CEO [1]. Group 2: Stock Performance - Shares of Teleflex fell by 11.32 percent, dropping $14.32 to $112.21 from a previous close of $126.53 [1][2]. - The stock opened at $112.50 and traded within a range of $108.39 to $115.00 during the session on the New York Stock Exchange [2]. - Trading volume reached approximately 1.38 million shares, significantly higher than the average volume of about 0.64 million shares [3]. Group 3: Historical Context - Teleflex's shares have fluctuated within a 52-week range of $102.58 to $185.94 [3].

Leadership Changes - Teleflex Incorporated has appointed Stuart Randle as Interim President and CEO, succeeding Liam Kelly, who has stepped down from his roles [1] - Stephen Klasko has been appointed as Chairman of the Board [1][2] Revenue Outlook - The company has lowered its full-year revenue outlook for 2025 to a range of $3.270 billion to $3.278 billion, down from the previous guidance of $3.305 billion to $3.320 billion [3] - The revision is attributed to softer-than-expected demand for intra-aortic balloon pumps and catheters in the U.S. and Asia, delays in certain OEM purchase orders, and lower overall order volumes across parts of its portfolio [3] Strategic Focus - Teleflex is transitioning to a more focused, higher-growth organization following the announced sale of its Acute Care, Interventional Urology, and OEM businesses [3] - The Board believes this leadership transition is timely to best position the company for future growth [3]

Financial Information - Teleflex Incorporated announced estimated preliminary financial information for the full year ended December 31, 2025, on January 8, 2026[4]. Leadership Changes - Liam J. Kelly departed as President and CEO effective January 7, 2026, with Stuart A. Randle appointed as Interim President and CEO starting January 8, 2026[5][6]. - The company is engaging Spencer Stuart to assist in the search for a permanent President and CEO[5]. Compensation and Benefits - Mr. Randle's compensation includes a monthly stipend of $140,000 and a restricted stock grant valued at $1.5 million, to be granted on January 13, 2026[10]. - Mr. Kelly's severance benefits are contingent upon his execution of a release of claims, with outstanding equity awards receiving age and service vesting treatment[11]. Transition Details - The transition matters were detailed in a press release dated January 8, 2026, which is attached as Exhibit 99.1[12].

Leadership Changes - Stuart Randle has been appointed as Interim President and CEO of Teleflex, succeeding Liam Kelly, who has departed from the company [1] - Dr. Stephen Klasko has been appointed as Chairman of the Board [1][2] - The Board has engaged Spencer Stuart to assist in the search for a permanent CEO [2] Business Strategy and Focus - Teleflex is transitioning to a more focused, higher-growth organization following the announced sale of its Acute Care, Interventional Urology, and OEM businesses [3] - The leadership transition is aimed at positioning the company for future growth in core critical care and high-acuity hospital markets [3] Financial Performance Update - The company expects full year 2025 revenue to be between $3.270 billion and $3.278 billion, a decrease from previous guidance of $3.305 billion to $3.320 billion [4] - The revenue reduction is primarily due to lower than expected demand for intra-aortic balloon pumps and catheters in the U.S. and Asia, as well as delays in OEM purchase orders [5] Future Reporting - Teleflex plans to report its full fourth quarter and full year 2025 financial results in late February or early March 2026 [7]

Core Insights - Teleflex's Interventional Urology portfolio is positioned for sustained growth, driven by UroLift's expanding global presence and strong clinical differentiation [1][3] - Barrigel enhances Teleflex's presence in prostate cancer care, supported by favorable clinical data and increasing clinician adoption [1][5] - High debt levels and adverse foreign exchange impacts are significant concerns for Teleflex [1][10][11] Financial Performance - Teleflex's stock has declined by 29.9% over the past year, while the industry has only dropped by 0.5%, and the S&P 500 has risen by 14.6% [2] - The company has a market capitalization of $5.52 billion and has consistently surpassed earnings estimates over the last four quarters, with an average surprise of 5.4% [2] Growth Drivers - UroLift is a minimally invasive device for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH), with enhanced market penetration in Japan and China [3] - Clinical studies have shown UroLift's superiority over competitors, particularly in early patient satisfaction and symptom relief [4] - Barrigel, a rectal spacer for prostate cancer radiation therapy, is gaining traction in the U.S. and Japan, with strong revenue momentum [5][6] Concerns - Teleflex's long-term debt reached $2.57 billion, a 42.7% increase sequentially, with a debt-to-capital ratio of 41.1% [10] - The company faces challenges from foreign exchange impacts, particularly due to a significant portion of revenues coming from international markets [11] Earnings Estimates - The Zacks Consensus Estimate for Teleflex's 2025 earnings per share (EPS) is $14.08, with revenues projected at $3.32 billion, indicating an 8.8% increase from the previous year [12]

Core Insights - The article promotes a premium service called "Value in Corporate Events" that focuses on major corporate events such as earnings reports, mergers and acquisitions, and IPOs, providing actionable investment ideas [1]. Group 1 - The service covers 10 major events each month, aiming to identify the best investment opportunities [1]. - The leader of the investing group has a Master of Science specializing in financial markets and a decade of experience in tracking companies through catalytic events [1]. - The service offers coverage of situations and names upon request, enhancing its tailored investment approach [1].

Core Viewpoint - Montagu and Kohlberg have entered into a definitive agreement to acquire Teleflex Medical OEM for $1.5 billion in a carve-out transaction from Teleflex Incorporated [1] Company Overview - Teleflex Medical OEM has over 40 years of experience in developing and supplying custom-engineered interventional catheter components, surgical fibers, and sutures, serving fast-growing treatment areas such as structural heart, neurovascular, electrophysiology, and urology [2] - The company operates seven state-of-the-art facilities across the U.S., Mexico, and Ireland, leveraging complex extrusion expertise and a vertically integrated operating model to support a blue-chip customer base in the medical device sector [2][6] Transaction Details - The transaction is expected to close in the second half of 2026, subject to regulatory approvals and other closing conditions, after which Teleflex Medical OEM will operate as an independent global contract developer and manufacturer [3] - Greg Stotts, currently the President and General Manager of Teleflex, will become the CEO post-transaction, bringing over 30 years of industry experience [3] Strategic Focus - The acquisition aims to accelerate investment in innovation, quality systems, and capacity while maintaining reliability and engineering depth for customers [4] - Montagu and Kohlberg plan to leverage their expertise in carve-out transactions and value creation to support Teleflex Medical OEM's growth and expansion of its customer base [4][5] Market Position - Teleflex Medical OEM is recognized as a leading strategic supplier in the global medtech value chain, known for its engineering support, reliability, and quality [5] - The company is positioned to create long-term, mutually beneficial partnerships with customers, addressing the increasing pressure on medical device companies to optimize portfolios and consolidate supply chains [5]